Xtant Medical (NYSEAMERICAN:XTNT) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as high as $0.38. Xtant Medical shares last traded at $0.36, with a volume of 209,214 shares.

Analysts Set New Price Targets

Separately, Craig Hallum set a $1.50 price target on Xtant Medical and gave the company a “buy” rating in a research note on Friday, October 18th.

Xtant Medical Stock Performance

The firm has a market capitalization of $50.04 million, a PE ratio of -2.77 and a beta of 0.34. The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42.

Xtant Medical (NYSEAMERICAN:XTNT) last issued its earnings results on Tuesday, November 12th. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). Xtant Medical had a negative return on equity of 37.07% and a negative net margin of 15.45%. The firm had revenue of $27.94 million during the quarter.

Hedge Funds Weigh In On Xtant Medical

An institutional investor recently bought a new position in Xtant Medical stock. Evernest Financial Advisors LLC acquired a new position in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 40,000 shares of the medical device company’s stock, valued at approximately $27,000. Hedge funds and other institutional investors own 69.33% of the company’s stock.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.